|
EP2445932B1
(en)
|
2009-06-26 |
2018-02-28 |
Soricimed Biopharma Inc. |
Soricidin derived peptides and methods for the detection of trpv-6 cancers and drug delivery
|
|
EP2545078A1
(en)
|
2010-03-11 |
2013-01-16 |
UCB Pharma, S.A. |
Pd-1 antibody
|
|
TW201134488A
(en)
*
|
2010-03-11 |
2011-10-16 |
Ucb Pharma Sa |
PD-1 antibodies
|
|
SI2699264T1
(en)
*
|
2011-04-20 |
2018-08-31 |
Medimmune Llc |
Antibodies and other molecules that bind b7-h1 and pd-1
|
|
PH12014500247A1
(en)
*
|
2011-07-29 |
2014-03-24 |
Univ Pennsylvania |
Switch costimulatory receptors
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
JP6742903B2
(ja)
|
2013-05-02 |
2020-08-19 |
アナプティスバイオ インコーポレイティッド |
プログラム死−１（ｐｄ−１）に対する抗体
|
|
CA2919725C
(en)
|
2013-08-08 |
2023-04-18 |
Cytune Pharma |
An il-15 and il-15r.aplha. sushi domain based modulokines
|
|
SI3030262T1
(sl)
|
2013-08-08 |
2020-03-31 |
Cytune Pharma |
Kombiniran farmacevtski sestavek
|
|
LT3702373T
(lt)
|
2013-09-13 |
2022-11-10 |
Beigene Switzerland Gmbh |
Anti-pd1 antikūnai ir jų naudojimas terapijai ir diagnostikai
|
|
EP3757130A1
(en)
|
2013-09-26 |
2020-12-30 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
|
HUE046249T2
(hu)
|
2013-12-12 |
2020-02-28 |
Shanghai hengrui pharmaceutical co ltd |
PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása
|
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗ｐｄ-ｌ１之人類抗體
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
CA2935423C
(en)
|
2014-01-24 |
2023-11-07 |
Dana-Farber Cancer Institute, Inc. |
Antibody molecules to pd-1 and uses thereof
|
|
AU2015210750B2
(en)
|
2014-01-31 |
2020-08-20 |
Children's Medical Center Corporation |
Antibody molecules to TIM-3 and uses thereof
|
|
WO2015138920A1
(en)
|
2014-03-14 |
2015-09-17 |
Novartis Ag |
Antibody molecules to lag-3 and uses thereof
|
|
TWI726608B
(zh)
|
2014-07-03 |
2021-05-01 |
英屬開曼群島商百濟神州有限公司 |
抗pd-l1抗體及其作為治療及診斷之用途
|
|
MX388181B
(es)
|
2014-07-22 |
2025-03-19 |
Cb Therapeutics Inc |
Anticuerpos anti-pd-1.
|
|
CA2957258C
(en)
*
|
2014-08-05 |
2023-11-07 |
MabQuest SA |
Immunological reagents
|
|
US9982052B2
(en)
*
|
2014-08-05 |
2018-05-29 |
MabQuest, SA |
Immunological reagents
|
|
JP6909153B2
(ja)
|
2014-08-05 |
2021-07-28 |
アポロミクス インコーポレイテッド |
抗ｐｄ−ｌ１抗体
|
|
WO2016040882A1
(en)
|
2014-09-13 |
2016-03-17 |
Novartis Ag |
Combination therapies of egfr inhibitors
|
|
WO2016057898A1
(en)
|
2014-10-10 |
2016-04-14 |
Idera Pharmaceuticals, Inc. |
Treatment of cancer using tlr9 agonist with checkpoint inhibitors
|
|
EP3943101A1
(en)
|
2014-10-21 |
2022-01-26 |
SciClone Pharmaceuticals International Ltd. |
Treatment of cancer with immune stimulator alpha thymosin peptide
|
|
SG11201704283PA
(en)
|
2014-11-26 |
2017-06-29 |
Xencor Inc |
Heterodimeric antibodies that bind cd3 and tumor antigens
|
|
BR112017024757A2
(pt)
|
2015-05-18 |
2018-11-13 |
TCR2 Therapeutics Inc. |
composições e métodos para reprogramação de tcr utilizando proteínas de fusão
|
|
US10874724B2
(en)
*
|
2015-05-22 |
2020-12-29 |
University Of Houston System |
Enzymatic immunomodulation of solid tumors and uses thereof
|
|
CN115927474A
(zh)
|
2015-06-19 |
2023-04-07 |
塞巴斯蒂安·科博尔德 |
Pd-1-cd28融合蛋白及其在医学中的用途
|
|
CA2991976A1
(en)
|
2015-07-13 |
2017-01-19 |
Cytomx Therapeutics, Inc. |
Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
|
|
CN116059219A
(zh)
|
2015-07-16 |
2023-05-05 |
比奥克斯塞尔医疗股份有限公司 |
一种使用免疫调节治疗癌症的新颖方法
|
|
ES2878188T3
(es)
|
2015-07-29 |
2021-11-18 |
Novartis Ag |
Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
|
|
KR20180036996A
(ko)
|
2015-08-04 |
2018-04-10 |
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 |
조합 치료 및 그의 용도 및 방법
|
|
EP3331918A1
(en)
|
2015-08-04 |
2018-06-13 |
GlaxoSmithKline Intellectual Property Development Limited |
Combination treatments and uses and methods thereof
|
|
EP3331919A1
(en)
|
2015-08-07 |
2018-06-13 |
GlaxoSmithKline Intellectual Property Development Limited |
Combination therapy comprising anti ctla-4 antibodies
|
|
WO2017024465A1
(en)
|
2015-08-10 |
2017-02-16 |
Innovent Biologics (Suzhou) Co., Ltd. |
Pd-1 antibodies
|
|
EP3344656A1
(en)
|
2015-09-01 |
2018-07-11 |
Agenus Inc. |
Anti-pd-1 antibodies and methods of use thereof
|
|
EP3355920A4
(en)
|
2015-09-29 |
2019-05-15 |
Celgene Corporation |
PD-1 BINDING PROTEINS AND METHOD OF USE THEREOF
|
|
DK3356411T3
(da)
|
2015-10-02 |
2021-09-06 |
Hoffmann La Roche |
Bispecifikke antistoffer, der er specifikke for PD1 og TIM3
|
|
US12030942B2
(en)
|
2015-10-02 |
2024-07-09 |
Les Laboratoires Servier |
Anti-PD-1 antibodies and compositions
|
|
AU2016333517B2
(en)
*
|
2015-10-02 |
2023-09-07 |
Les Laboratoires Servier |
Anti-PD-1 antibodies and compositions
|
|
AU2016329251B2
(en)
|
2015-10-02 |
2023-02-02 |
F. Hoffmann-La Roche Ag |
Anti-PD1 antibodies and methods of use
|
|
KR20250099459A
(ko)
|
2015-11-03 |
2025-07-01 |
얀센 바이오테크 인코포레이티드 |
Pd-1과 특이적으로 결합하는 항체 및 그의 용도
|
|
HUE063377T2
(hu)
|
2015-12-22 |
2024-01-28 |
Regeneron Pharma |
Anti-PD-1 antitestek és bispecifikus anti-CD20/anti-CD3 antitestek kombinációja a rák kezelésére
|
|
ES3034233T3
(en)
|
2016-01-22 |
2025-08-14 |
MabQuest SA |
Non-blocking pd1 specific antibodies
|
|
BR112018068461A2
(pt)
|
2016-03-15 |
2019-01-22 |
Mersana Therapeutics Inc |
conjugado, composição farmacêutica, métodos para preparação de um conjugado e para alívio de um sintoma de um câncer.
|
|
WO2017165742A1
(en)
|
2016-03-24 |
2017-09-28 |
Millennium Pharmaceuticals, Inc. |
Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
|
|
EP3433275A1
(en)
|
2016-03-24 |
2019-01-30 |
Millennium Pharmaceuticals, Inc. |
Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
|
|
EP3243832A1
(en)
|
2016-05-13 |
2017-11-15 |
F. Hoffmann-La Roche AG |
Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
|
|
TWI786044B
(zh)
|
2016-05-13 |
2022-12-11 |
美商再生元醫藥公司 |
藉由投予ｐｄ-１抑制劑治療皮膚癌之方法
|
|
CN106008714B
(zh)
*
|
2016-05-24 |
2019-03-15 |
瑞阳(苏州)生物科技有限公司 |
抗人pd-1人源化单克隆抗体及其应用
|
|
MA45255A
(fr)
*
|
2016-06-14 |
2019-04-17 |
Xencor Inc |
Anticorps inhibiteurs de points de contrôle bispécifiques
|
|
JP7461741B2
(ja)
|
2016-06-20 |
2024-04-04 |
カイマブ・リミテッド |
抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
|
|
WO2018007885A1
(en)
|
2016-07-05 |
2018-01-11 |
Beigene, Ltd. |
COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER
|
|
US11649289B2
(en)
|
2016-08-04 |
2023-05-16 |
Glaxosmithkline Intellectual Property Development Limited |
Anti-ICOS and anti-PD-1 antibody combination therapy
|
|
AU2017313085B2
(en)
|
2016-08-19 |
2024-06-20 |
Beone Medicines I Gmbh |
Use of a combination comprising a Btk inhibitor for treating cancers
|
|
WO2018053405A1
(en)
|
2016-09-19 |
2018-03-22 |
Celgene Corporation |
Methods of treating immune disorders using pd-1 binding proteins
|
|
EP3515943A4
(en)
|
2016-09-19 |
2020-05-06 |
Celgene Corporation |
METHODS OF TREATING VITILIGO WITH PD-1 BINDING PROTEINS
|
|
CN114456269A
(zh)
*
|
2016-09-21 |
2022-05-10 |
基石药业（苏州）有限公司 |
一种新的pd-1单克隆抗体
|
|
US12098202B2
(en)
|
2016-10-10 |
2024-09-24 |
The National Institute for Biotechnology in the Negev Ltd. |
Non-cytotoxic modified cells and use thereof
|
|
EP3666794A1
(en)
|
2016-11-01 |
2020-06-17 |
AnaptysBio, Inc. |
Antibodies directed against programmed death- 1 (pd-1)
|
|
TW201829462A
(zh)
|
2016-11-02 |
2018-08-16 |
英商葛蘭素史克智慧財產（第二）有限公司 |
結合蛋白
|
|
US11359018B2
(en)
|
2016-11-18 |
2022-06-14 |
Symphogen A/S |
Anti-PD-1 antibodies and compositions
|
|
AU2017363311A1
(en)
|
2016-11-22 |
2019-06-13 |
TCR2 Therapeutics Inc. |
Compositions and methods for TCR reprogramming using fusion proteins
|
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
|
BR112019011350A2
(pt)
|
2016-12-01 |
2019-10-22 |
Glaxosmithkline Ip Dev Ltd |
terapia de combinação
|
|
WO2018100534A1
(en)
|
2016-12-01 |
2018-06-07 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapy
|
|
CN118634323A
(zh)
|
2016-12-07 |
2024-09-13 |
艾吉纳斯公司 |
抗体和其使用方法
|
|
EP3565844B8
(en)
|
2017-01-09 |
2023-04-12 |
Tesaro, Inc. |
Methods of treating cancer with anti-pd-1 antibodies
|
|
WO2018137681A1
(en)
|
2017-01-25 |
2018-08-02 |
Beigene, Ltd. |
Crystalline forms of (s) -7- (1- (but-2-ynoyl) piperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahy dropyrazolo [1, 5-a] pyrimidine-3-carboxamide, preparation, and uses thereof
|
|
EP3582855A1
(en)
|
2017-02-15 |
2019-12-25 |
GlaxoSmithKline Intellectual Property Development Limited |
Combination treatment for cancer
|
|
WO2018160538A1
(en)
|
2017-02-28 |
2018-09-07 |
Mersana Therapeutics, Inc. |
Combination therapies of her2-targeted antibody-drug conjugates
|
|
JP7165717B2
(ja)
|
2017-03-15 |
2022-11-04 |
パンディオン・オペレーションズ・インコーポレイテッド |
標的免疫寛容
|
|
EP4201953A1
(en)
|
2017-04-03 |
2023-06-28 |
F. Hoffmann-La Roche AG |
Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
|
|
SG11201909154SA
(en)
|
2017-04-05 |
2019-10-30 |
Hoffmann La Roche |
Bispecific antibodies specifically binding to pd1 and lag3
|
|
KR102737715B1
(ko)
|
2017-04-05 |
2024-12-03 |
르 라보레또레 쎄르비에르 |
Pd-1, tim-3 및 lag-3을 표적화하는 조합 요법
|
|
US11603407B2
(en)
|
2017-04-06 |
2023-03-14 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
|
AU2018273914A1
(en)
|
2017-05-24 |
2019-11-14 |
Pandion Operations, Inc. |
Targeted immunotolerance
|
|
CR20190550A
(es)
|
2017-06-05 |
2020-04-05 |
Janssen Biotech Inc |
Anticuerpos que se unen específicamente a pd-1 y métodos de uso
|
|
CA3066048A1
(en)
|
2017-06-09 |
2018-12-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapy
|
|
KR102757960B1
(ko)
|
2017-06-26 |
2025-01-22 |
베이진 엘티디 |
간세포암(hepatocellular carcinoma: HCC)에 대한 면역 치료
|
|
EA202090005A1
(ru)
|
2017-07-06 |
2020-06-18 |
Мерус Н.В. |
Антитела, модулирующие биологическую активность, проявляемую клеткой
|
|
AU2018366199A1
(en)
|
2017-11-08 |
2020-05-28 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-PD-1 sequences
|
|
EP3717021A1
(en)
|
2017-11-27 |
2020-10-07 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepine antibody conjugates
|
|
CN111801334B
(zh)
|
2017-11-29 |
2023-06-09 |
百济神州瑞士有限责任公司 |
使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤
|
|
US10174091B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
|
US10946068B2
(en)
|
2017-12-06 |
2021-03-16 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
USRE50550E1
(en)
|
2017-12-06 |
2025-08-26 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
JP2021506883A
(ja)
|
2017-12-21 |
2021-02-22 |
メルサナ セラピューティクス インコーポレイテッド |
ピロロベンゾジアゼピン抗体結合体
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
CN111655730A
(zh)
|
2018-01-31 |
2020-09-11 |
豪夫迈·罗氏有限公司 |
包含与lag3结合的抗原结合位点的双特异性抗体
|
|
TWI708787B
(zh)
*
|
2018-03-02 |
2020-11-01 |
美商美國禮來大藥廠 |
Pd-1促效劑抗體及其用途
|
|
US11505610B2
(en)
|
2018-04-06 |
2022-11-22 |
Atyr Pharma, Inc. |
Compositions and methods comprising anti-NRP2 antibodies
|
|
US20210363216A1
(en)
|
2018-05-14 |
2021-11-25 |
Immunocore Limited |
Bifunctional binding polypeptides
|
|
MA52889A
(fr)
|
2018-06-15 |
2021-04-21 |
Flagship Pioneering Innovations V Inc |
Augmentation de l'activité immunitaire par modulation de facteurs de signalisation post-cellulaires
|
|
JP7490925B2
(ja)
|
2018-07-26 |
2024-05-28 |
エータイアー ファーマ， インコーポレイテッド |
Ｎｒｐ２関連疾患を治療するための組成物および方法
|
|
WO2020030571A1
(en)
|
2018-08-06 |
2020-02-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combinations of a pd-1 antibody and a tlr4 modulator and uses thereof
|
|
AU2019366321A1
(en)
|
2018-10-22 |
2021-05-13 |
Glaxosmithkline Intellectual Property Development Limited |
Dosing
|
|
MX2021004906A
(es)
|
2018-10-29 |
2021-09-10 |
Mersana Therapeutics Inc |
Conjugados de anticuerpo modificado con cisteína-fármaco con enlazadores que contienen péptidos.
|
|
WO2020097495A1
(en)
|
2018-11-09 |
2020-05-14 |
Pierian Biosciences, LLC |
Methods and compositions for determining the composition of a tumor microenvironment
|
|
GB201820547D0
(en)
|
2018-12-17 |
2019-01-30 |
Oxford Univ Innovation |
Modified antibodies
|
|
US20220107320A1
(en)
|
2019-02-15 |
2022-04-07 |
Incelldx, Inc. |
Assaying Bladder-Associated Samples, Identifying and Treating Bladder-Associated Neoplasia, and Kits for Use Therein
|
|
US12404331B2
(en)
|
2019-04-19 |
2025-09-02 |
Tcrcure Biopharma Corp. |
Anti-PD-1 antibodies and uses thereof
|
|
EP3962493A2
(en)
|
2019-05-03 |
2022-03-09 |
Flagship Pioneering Innovations V, Inc. |
Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
|
|
CA3141327A1
(en)
|
2019-05-20 |
2020-11-26 |
Pandion Operations, Inc. |
Madcam targeted immunotolerance
|
|
JP7490679B2
(ja)
*
|
2019-06-05 |
2024-05-27 |
アナプティスバイオ インコーポレイティッド |
Ｐｄ－１アゴニストおよびそれを使用する方法
|
|
US11246906B2
(en)
|
2019-06-11 |
2022-02-15 |
Alkermes Pharma Ireland Limited |
Compositions and methods for subcutaneous administration of cancer immunotherapy
|
|
KR20220041080A
(ko)
|
2019-06-18 |
2022-03-31 |
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 |
B형 간염 바이러스(hbv) 백신 및 항-pd-1 또는 항-pc-l1 항체의 조합
|
|
AU2020296372A1
(en)
|
2019-06-18 |
2022-02-17 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis B virus (HBV) vaccines and anti-PD-1 antibody
|
|
KR20220030956A
(ko)
|
2019-07-05 |
2022-03-11 |
오노 야꾸힝 고교 가부시키가이샤 |
Pd-1/cd3 이중 특이성 단백질에 의한 혈액암 치료
|
|
TW202120550A
(zh)
|
2019-08-08 |
2021-06-01 |
日商小野藥品工業股份有限公司 |
雙特異性蛋白質
|
|
KR20220100859A
(ko)
|
2019-09-17 |
2022-07-18 |
비알 - 알&디 인베스트먼츠, 에스.에이. |
산성 세라미다아제 저해제로서의 치환된 n-헤테로시클릭 카르복사미드, 및 약제로서의 이의 용도
|
|
EP4031540A1
(en)
|
2019-09-17 |
2022-07-27 |
Bial-R&D Investments, S.A. |
Substituted, saturated and unsaturated n-heterocyclic carboxamides and related compounds for their use in the treatment of medical disorders
|
|
KR20220100858A
(ko)
|
2019-09-17 |
2022-07-18 |
비알 - 알&디 인베스트먼츠, 에스.에이. |
치환된 이미다졸 카르복사미드, 및 질병의 치료에서의 이의 용도
|
|
US20230114107A1
(en)
|
2019-12-17 |
2023-04-13 |
Flagship Pioneering Innovations V, Inc. |
Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
|
|
WO2021168079A1
(en)
|
2020-02-21 |
2021-08-26 |
Pandion Operations, Inc. |
Tissue targeted immunotolerance with a cd39 effector
|
|
AU2021357520A1
(en)
|
2020-03-05 |
2022-09-29 |
Neotx Therapeutics Ltd. |
Methods and compositions for treating cancer with immune cells
|
|
US20230131598A1
(en)
|
2020-04-14 |
2023-04-27 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatment for cancer
|
|
WO2021209357A1
(en)
|
2020-04-14 |
2021-10-21 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatment for cancer involving anti-icos and anti-pd1 antibodies, optionally further involving anti-tim3 antibodies
|
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
|
MA59827B1
(fr)
*
|
2020-05-26 |
2024-10-31 |
Boehringer Ingelheim International Gmbh |
Anticorps anti-pd-1
|
|
EP4172323A1
(en)
|
2020-06-29 |
2023-05-03 |
Flagship Pioneering Innovations V, Inc. |
Viruses engineered to promote thanotransmission and their use in treating cancer
|
|
CN116157513A
(zh)
|
2020-08-18 |
2023-05-23 |
昂希莱斯制药公司 |
经修饰的猪胰腺弹性蛋白酶蛋白
|
|
PH12023500013A1
(en)
|
2020-12-04 |
2024-03-11 |
Tidal Therapeutics Inc |
Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
|
|
KR20230156079A
(ko)
|
2021-03-09 |
2023-11-13 |
젠코어 인코포레이티드 |
Cd3과 cldn6에 결합하는 이종이량체 항체
|
|
MX2023011663A
(es)
|
2021-03-31 |
2023-10-11 |
Merus Nv |
Dominios de union a pd-1 novedosos.
|
|
US20220325287A1
(en)
|
2021-03-31 |
2022-10-13 |
Flagship Pioneering Innovations V, Inc. |
Thanotransmission polypeptides and their use in treating cancer
|
|
GB202107994D0
(en)
|
2021-06-04 |
2021-07-21 |
Kymab Ltd |
Treatment of cancer
|
|
CN115466328B
(zh)
*
|
2021-06-11 |
2025-09-12 |
广东菲鹏制药股份有限公司 |
抗pd-1人源化抗体或其抗原结合片段及其应用
|
|
KR20240026507A
(ko)
|
2021-06-29 |
2024-02-28 |
플래그쉽 파이어니어링 이노베이션스 브이, 인크. |
타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도
|
|
US20250215103A1
(en)
|
2021-08-03 |
2025-07-03 |
Hoffmann-La Roche Inc. |
Bispecific antibodies and methods of use
|
|
WO2023028501A1
(en)
|
2021-08-23 |
2023-03-02 |
Immunitas Therapeutics, Inc. |
Anti-cd161 antibodies and uses thereof
|
|
EP4433507A2
(en)
|
2021-11-19 |
2024-09-25 |
MiroBio Limited |
Pd-1 antibodies and uses thereof
|
|
AR129560A1
(es)
|
2022-06-08 |
2024-09-04 |
Tidal Therapeutics Inc |
Lípidos catiónicos ionizables y nanopartículas lipídicas, y métodos de síntesis y uso de los mismos
|
|
IL318931A
(en)
|
2022-08-18 |
2025-04-01 |
Immunocore Ltd |
Multi-domain binding molecules
|
|
MX2025001960A
(es)
|
2022-08-18 |
2025-05-02 |
Immunocore Ltd |
Moléculas de unión multidominio
|
|
WO2024077191A1
(en)
|
2022-10-05 |
2024-04-11 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
|
|
WO2024086827A2
(en)
|
2022-10-20 |
2024-04-25 |
Repertoire Immune Medicines, Inc. |
Cd8 t cell targeted il2
|
|
WO2024092031A1
(en)
|
2022-10-25 |
2024-05-02 |
Seismic Therapeutic, Inc. |
VARIANT IgG FC POLYPEPTIDES AND USES THEREOF
|
|
TW202430560A
(zh)
|
2023-01-06 |
2024-08-01 |
美商拉森醫療公司 |
抗ｉｌ－１８ｂｐ抗體
|
|
JP2026503273A
(ja)
|
2023-01-06 |
2026-01-28 |
ラッセン・セラピューティクス・インコーポレイテッド |
抗ｉｌ－１８ｂｐ抗体
|
|
US20240269251A1
(en)
|
2023-01-09 |
2024-08-15 |
Flagship Pioneering Innovations V, Inc. |
Genetic switches and their use in treating cancer
|
|
CN120813375A
(zh)
|
2023-01-30 |
2025-10-17 |
凯玛布有限公司 |
抗体
|
|
GB202306345D0
(en)
|
2023-04-28 |
2023-06-14 |
Immunocore Ltd |
Binding molecules
|
|
EP4709756A1
(en)
|
2023-05-10 |
2026-03-18 |
Regeneron Pharmaceuticals, Inc. |
Cd20-pd1 binding molecules and methods of use thereof
|
|
WO2024243189A2
(en)
*
|
2023-05-22 |
2024-11-28 |
Board Of Regents, The University Of Texas System |
Antigen binding proteins targeting pd-1
|
|
GB202315181D0
(en)
|
2023-10-03 |
2023-11-15 |
Immunocore Ltd |
Peptide-HLA binding molecules
|
|
GB202320012D0
(en)
|
2023-12-22 |
2024-02-07 |
Immunocore Ltd |
Bispecific molecules
|
|
WO2025146662A1
(en)
|
2024-01-05 |
2025-07-10 |
Immunocore Limited |
Cd1a-pd-1 bispecific agonist for the treatment of atopic dermatitis
|
|
TW202543581A
(zh)
|
2024-02-12 |
2025-11-16 |
美商艾伊拉醫療公司 |
遞送組成物
|
|
TW202602455A
(zh)
|
2024-03-26 |
2026-01-16 |
美商安進公司 |
使用ｍｔａ協作的ｐｒｍｔ５抑制劑的癌症治療
|
|
TW202606706A
(zh)
|
2024-04-05 |
2026-02-16 |
美商安進公司 |
使用ｍｔａ協作的ｐｒｍｔ５抑制劑的胃腸癌治療
|
|
WO2025224084A1
(en)
|
2024-04-22 |
2025-10-30 |
Engimmune Therapeutics Ag |
Proteins comprising t cell receptor constant domains
|
|
WO2026003224A2
(en)
|
2024-06-26 |
2026-01-02 |
Iomx Therapeutics Ag |
Bispecific antigen binding proteins (abp) targeting immune checkpoint molecules and both leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2; combinations and uses thereof
|
|
WO2026072557A2
(en)
|
2024-09-24 |
2026-04-02 |
Genzyme Corporation |
Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
|